Dementia Associated With Alzheimers Disease - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 57 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2014', provides an overview of the Dementia Associated With Alzheimer's Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia Associated With Alzheimer's Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dementia Associated With Alzheimer's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dementia Associated With Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dementia Associated With Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dementia Associated With Alzheimer's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dementia Associated With Alzheimer's Disease Overview 6
Therapeutics Development 7
Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview 7
Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis 8
Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies 9
Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 10
Dementia Associated With Alzheimer's Disease - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Dementia Associated With Alzheimer's Disease - Products under Development by Companies 14
Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes 15
Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development 16
FORUM Pharmaceuticals Inc. 16
Kowa Company, Ltd. 17
Adamas Pharmaceuticals, Inc. 18
Otsuka Holdings Co., Ltd. 19
Chase Pharmaceuticals Corporation 20
Dementia Associated With Alzheimer's Disease - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 30
(memantine hydrochloride ER + donepezil hydrochloride) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
brexpiprazole - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
aripiprazole - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
encenicline hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
K-828-AB - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CPC-201 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TAK-070 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AVCRI-104P3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Dementia Associated With Alzheimer's Disease - Recent Pipeline Updates 43
Dementia Associated With Alzheimer's Disease - Dormant Projects 50
Dementia Associated With Alzheimer's Disease - Discontinued Products 51
Dementia Associated With Alzheimer's Disease - Product Development Milestones 52
Featured News & Press Releases 52
May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories 52
Jan 31, 2014: Forest Laboratories Files Lawsuit Against Several Companies for Infringement of NAMENDA XR Patents 52
Jun 13, 2013: Forest Labs Announces US Availability Of New Once-daily Namenda XR 52
Oct 26, 2012: New Research Demonstrates Potential Of IRX4204 For Reduction Of Dementia In Animal Models Of Alzheimer's And Parkinson's Disease 53
May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda 54
Jun 03, 2011: IQWiG Recognizes Benefits Of Memantine 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

List of Tables
Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2014 7
Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Dementia Associated With Alzheimer's Disease - Pipeline by FORUM Pharmaceuticals Inc., H2 2014 16
Dementia Associated With Alzheimer's Disease - Pipeline by Kowa Company, Ltd., H2 2014 17
Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 18
Dementia Associated With Alzheimer's Disease - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 19
Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Assessment by Combination Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 29
Dementia Associated With Alzheimer's Disease Therapeutics - Recent Pipeline Updates, H2 2014 43
Dementia Associated With Alzheimer's Disease - Dormant Projects, H2 2014 50
Dementia Associated With Alzheimer's Disease - Discontinued Products, H2 2014 51